In genetic models, low serum APN can promote breast and colon cancer development through angiogenic mechanisms and by modulating the AMPK-activated protein kinase (AMPK)/mammalian target of Rapamycin (mTOR) pathway [18, 19]. Here, MTOR is linked to colonic neoplasm.